COVID-19 Monoclonal Antibody Infusion Administration Code (UB-04 Billing)

<p>Blue Cross and Blue Shield of Kansas (BCBSKS) continues to monitor COVID-19 and the changes with billing new codes. As of May 1,2021, the following new codes will be reimbursed as follows:</p> <table> <thead> <tr> <th>HCPCS Code</th> <th>Nomenclature</th> <th>MAP'd like:</th> </tr> </thead> <tbody> <tr> <td>M0245</td> <td>INTRAVENOUS INFUSION, BAMLANIVIMAB AND ETESEVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING</td> <td>M0239<br><br /> M0243</td> </tr> </tbody> </table> <p>If you have any questions regarding this newsletter, please contact your <a href="/providers/institutional/contact-us">BCBSKS Institutional Relations provider consultant</a>.</p>